Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Zilli

Showing results (11-20 of 234) with videos related to

Pageof 24
Sort By:
European Urology|December 13, 2025
Re: Markus Graefen, Fabian Falkenbach, Tobias Maurer, et al. Best Systemic Therapy With or Without Radical Prostatectomy in the Management of Men With Oligometastatic Prostate Cancer: The RAMPP Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2025.09.4144Salvatore Cozzi, Thomas Zilli
International Journal of Urology : Official Journal of the Japanese Urological Association|September 9, 2014
Editorial Comment from Dr Zilli and Dr Miralbell to Early radiotherapy after radical prostatectomy improves cancer-specific survival only in patients with highly aggressive prostate cancer: validation of recently released criteriaThomas Zilli, Raymond Miralbell
The Lancet. Oncology|July 31, 2025
Reflections on the PEACE V-STORM trial - Authors' replyPiet Ost, Thomas Zilli,
Clinical and Translational Radiation Oncology|March 21, 2023
Prostate cancer radiotherapy and incidental testicular irradiation: Impact on gonadal functionJennifer Le Guevelou, Thomas Zilli
European Urology Open Science|October 29, 2025
Unlocking New Therapeutic Strategies in Oligometastatic Prostate Cancer with Radioligand and Metastasis-directed Radiation TherapySalvatore Cozzi, Camille Roukoz, Thomas Zilli
International Journal of Radiation Oncology, Biology, Physics|March 23, 2020
Letter from SwitzerlandVérane Achard, Pelagia Tsoutsou, Thomas Zilli
European Urology|August 2, 2021
Everything But the Kitchen Sink: Comprehensive Nodal Irradiation with Androgen Deprivation in OLIGOPELVISPiet Ost, Shankar Siva, Thomas Zilli
European Urology Focus|November 8, 2025
Re: Carlo Andrea Bravi, Sophie Knipper, Axel Heidenreich, et al. Oncologic Outcomes of Template Versus Radioguided Salvage Lymph Node Dissection for Node-only Recurrent Prostate Cancer on Prostate-specific Membrane Antigen Positron Emission Tomography Scan: Results from a Multi-institutional Collaboration. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2025.05.019Giulio Francolini, Piet Ost, Thomas Zilli
European Urology|April 28, 2024
OLIGOPELVIS and the "All You Can Eat" Strategy for Oligorecurrent Nodal Prostate Cancer: Are We Already Full?Piet Ost, Shankar Siva, Thomas Zilli
European Urology Open Science|February 3, 2026
Re: Amar U. Kishan, Luca F. Valle, Holly Wilhalme, et al. <sup>177</sup>Lu-Prostate-specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-label, Randomized, Controlled, Phase II Study. J Clin Oncol 2025;43:3812-21Vérane Achard, Thomas Zilli, Bertrand Tombal
Pageof 24

Showing results (11-20 of 234) with videos related to

Sort By:
Pageof 24
European Urology|December 13, 2025
Re: Markus Graefen, Fabian Falkenbach, Tobias Maurer, et al. Best Systemic Therapy With or Without Radical Prostatectomy in the Management of Men With Oligometastatic Prostate Cancer: The RAMPP Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2025.09.4144Salvatore Cozzi, Thomas Zilli
International Journal of Urology : Official Journal of the Japanese Urological Association|September 9, 2014
Editorial Comment from Dr Zilli and Dr Miralbell to Early radiotherapy after radical prostatectomy improves cancer-specific survival only in patients with highly aggressive prostate cancer: validation of recently released criteriaThomas Zilli, Raymond Miralbell
The Lancet. Oncology|July 31, 2025
Reflections on the PEACE V-STORM trial - Authors' replyPiet Ost, Thomas Zilli,
Clinical and Translational Radiation Oncology|March 21, 2023
Prostate cancer radiotherapy and incidental testicular irradiation: Impact on gonadal functionJennifer Le Guevelou, Thomas Zilli
European Urology Open Science|October 29, 2025
Unlocking New Therapeutic Strategies in Oligometastatic Prostate Cancer with Radioligand and Metastasis-directed Radiation TherapySalvatore Cozzi, Camille Roukoz, Thomas Zilli
International Journal of Radiation Oncology, Biology, Physics|March 23, 2020
Letter from SwitzerlandVérane Achard, Pelagia Tsoutsou, Thomas Zilli
European Urology|August 2, 2021
Everything But the Kitchen Sink: Comprehensive Nodal Irradiation with Androgen Deprivation in OLIGOPELVISPiet Ost, Shankar Siva, Thomas Zilli
European Urology Focus|November 8, 2025
Re: Carlo Andrea Bravi, Sophie Knipper, Axel Heidenreich, et al. Oncologic Outcomes of Template Versus Radioguided Salvage Lymph Node Dissection for Node-only Recurrent Prostate Cancer on Prostate-specific Membrane Antigen Positron Emission Tomography Scan: Results from a Multi-institutional Collaboration. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2025.05.019Giulio Francolini, Piet Ost, Thomas Zilli
European Urology|April 28, 2024
OLIGOPELVIS and the "All You Can Eat" Strategy for Oligorecurrent Nodal Prostate Cancer: Are We Already Full?Piet Ost, Shankar Siva, Thomas Zilli
European Urology Open Science|February 3, 2026
Re: Amar U. Kishan, Luca F. Valle, Holly Wilhalme, et al. <sup>177</sup>Lu-Prostate-specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-label, Randomized, Controlled, Phase II Study. J Clin Oncol 2025;43:3812-21Vérane Achard, Thomas Zilli, Bertrand Tombal
Pageof 24